Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Necitumumab + Trastuzumab + Osimertinib for Lung Cancer
Recruiting1 awardPhase 1 & 2
Los Angeles, California
This trial is testing the side effects and best dose of trastuzumab and necitumumab given with osimertinib, to treat patients with stage IV EGFR-mutated non-small cell lung cancer that is resistant to osimertinib and has not responded to previous treatment.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.